Ken Griffin Deciphera Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$13.58 - $17.36 $61,110 - $78,120	4,500 Added 1500.0%	4,800 $75,000
Q4 2023 Feb 14, 2024	SELL	$10.11 - $16.54 $34,374 - $56,236	-3,400 Reduced 91.89%	300 $4,000
Q3 2023 Nov 14, 2023	BUY	$12.46 - $15.48 $46,102 - $57,276	3,700 New	3,700 $47,000
Q1 2023 May 15, 2023	SELL	$14.26 - $22.1 $1.09 Million - $1.69 Million	-76,600 Reduced 84.64%	13,900 $214,000
Q4 2022 Feb 14, 2023	SELL	$14.85 - $19.04 $60,885 - $78,064	-4,100 Reduced 4.33%	90,500 $1.48 Million
Q3 2022 Nov 14, 2022	SELL	$12.38 - $20.23 $814,604 - $1.33 Million	-65,800 Reduced 41.02%	94,600 $1.75 Million

293K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.